TechForce Robotics, Inc., the acting subsidiary of Nightfood Holdings, Inc. (OTCQB: NGTF), has completed the initial deployment of its LIM-E autonomous laboratory support robot at Oncotelic Therapeutics. This deployment fulfills Phase 1 objectives under a joint development agreement designed to evaluate robotics and AI-enhanced systems for future GMP-regulated pharmaceutical manufacturing and laboratory workflows. The move marks the company's first operational entry into pharmaceutical and laboratory automation, extending its Robotics-as-a-Service (RaaS) platform from hospitality into a new vertical.
Laboratory and pharmaceutical operations increasingly face the same challenge that has accelerated automation across industries from manufacturing to hospitality: how to improve efficiency while freeing highly trained personnel to focus on higher-value work. Researchers, technicians, and production staff often spend significant time on routine logistics tasks that, while necessary, do not directly advance scientific work, product development, or manufacturing output. As labor costs rise and productivity demands grow, pharmaceutical and biotechnology organizations are exploring automation solutions capable of supporting operational scalability without disrupting tightly regulated workflows. TechForce Robotics is positioning itself to address that opportunity by extending its RaaS platform into laboratory automation.
A new strategic alliance with JJ Enterprise adds advanced manufacturing, machine vision, and precision engineering expertise that could support the expansion of high-precision AI-driven applications. This partnership is expected to enhance the capabilities of TechForce's robotic systems, enabling more sophisticated tasks in controlled environments. The company's focus on RaaS allows clients to adopt automation without large upfront capital investments, which is particularly attractive in industries where budgets are constrained and regulatory compliance is critical.
The implications of this announcement are significant for the pharmaceutical industry, as automation can reduce human error, increase throughput, and allow scientists to concentrate on drug discovery and development. For TechForce, success in this sector could open up a large new revenue stream and validate its technology beyond hospitality. Investors should note that the company's progress in this area will be closely watched, and further updates are expected as the joint development agreement progresses. More information about the company is available in its newsroom at https://ibn.fm/NGTF.
